Bempedoic Acid

證據等級: L5

預測適應症: 10 個

Bempedoic Acid: From Primary Hypercholesterolemia to Homozygous Familial Hypercholesterolemia

One-Sentence Summary

Bempedoic Acid is an ATP-Citrate Lyase (ACL) inhibitor FDA-approved in the United States (as Nexletol®) for LDL-cholesterol reduction in adults with primary hypercholesterolemia or heterozygous familial hypercholesterolemia (HeFH), but is not yet marketed in Taiwan. The TxGNN model’s top-ranked prediction is hyperthyroidism (score 99.61%), though this carries no mechanistic basis and a Hold recommendation; the most clinically actionable prediction is Homozygous Familial Hypercholesterolemia (HoFH) (rank 6, score 99.48%), with 0 clinical trials and 17 publications — including a 2026 real-world study that directly evaluated bempedoic acid in HoFH patients.

Quick Overview

Item	Content
Original Indication	Primary Hypercholesterolemia / Heterozygous Familial Hypercholesterolemia (FDA-approved; not yet approved in Taiwan)
Predicted New Indication	Homozygous Familial Hypercholesterolemia (HoFH)
TxGNN Prediction Score	99.48% (rank 6 overall)
Evidence Level	L3 — Observational studies and systematic reviews
Taiwan Market Status	✗ Not marketed (0 Taiwan TFDA licenses)
Number of Taiwan Licenses	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Bempedoic acid inhibits ATP-Citrate Lyase (ACL), an enzyme that sits upstream of HMG-CoA reductase in the hepatic cholesterol biosynthesis pathway. By blocking ACL, the drug reduces intracellular acetyl-CoA availability for cholesterol synthesis, which in turn upregulates hepatic LDL receptor (LDLR) expression and enhances plasma LDL clearance. Importantly, bempedoic acid requires activation by the liver-specific enzyme ACSVL1, which confines its activity to the liver and avoids the skeletal muscle exposure responsible for statin-induced myopathy — a key clinical advantage for statin-intolerant patients.

The mechanistic link between HeFH (the approved indication) and HoFH is direct: both diseases stem from LDLR gene mutations, differing only in severity. In HeFH, one functional LDLR allele remains, allowing LDLR-upregulating therapies to work well. In HoFH, both alleles are non-functional or severely impaired, which theoretically limits the LDLR-dependent component of bempedoic acid’s effect. However, ACL inhibition also reduces hepatic VLDL secretion — a pathway independent of LDLR — providing partial LDL-C lowering even without functional receptors. This makes extension from HeFH to HoFH mechanistically plausible, though the expected magnitude of effect is smaller.

The literature base further supports this reasoning. A 2026 real-world study (Warden & Duell, PMID 41274797) directly evaluated bempedoic acid efficacy and tolerability in HoFH patients. Multiple expert reviews from 2021–2025 consistently position bempedoic acid as part of the combination therapy armamentarium for refractory familial hypercholesterolemia, particularly for patients who cannot tolerate statins. A 2018 large-animal study (PMID 29449335) demonstrated LDL-C lowering and atherosclerosis attenuation in LDLR-deficient Yucatan miniature pigs — a direct HoFH model — providing early mechanistic proof-of-concept.

Clinical Trial Evidence

Currently no related clinical trials registered for bempedoic acid in homozygous familial hypercholesterolemia.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
41274797	2026	Real-World Study	J Clin Lipidology	Direct retrospective evaluation of bempedoic acid efficacy and tolerability specifically in HoFH patients
33766264	2021	Expert Review	JACC	Bempedoic acid as an emerging LDL-lowering therapy; discusses its role in FH management alongside PCSK9i and inclisiran
35466160	2022	Narrative Review	J Atherosclerosis & Thrombosis	HoFH treatment advances; highlights challenges of LDL-C reduction when LDLR function is absent and discusses emerging agents
41106315	2025	Narrative Review	Exp Mol Pathology	Innovative therapies for HoFH; covers ACL inhibition approach and combination strategies
37071085	2024	Drug Review	Cardiology in Review	Reviews lipid-lowering options for FH including bempedoic acid as adjunct to evinacumab and other agents
38576462	2024	Review	Am J Preventive Cardiology	Comprehensive review of LDL-C lowering strategies; positions bempedoic acid within the treatment hierarchy for difficult-to-treat dyslipidemia
34081216	2021	Review	Current Cardiology Reports	Management of familial and refractory hypercholesterolemias beyond statins and PCSK9 inhibitors; includes bempedoic acid discussion
37979722	2024	Review	Indian Heart Journal	Non-statin lipid-lowering drugs including bempedoic acid; covers indications in statin intolerance and residual LDL risk
32243228	2020	Review	Postgraduate Medicine	Bempedoic acid as an emerging LDL-lowering agent targeting ApoB lipoproteins for ASCVD prevention
29449335	2018	Animal Study	Arteriosclerosis, Thrombosis & Vascular Biology	Bempedoic acid lowers LDL-C and attenuates atherosclerosis in LDLR-deficient (LDLR+/− and LDLR−/−) Yucatan miniature pigs — a direct HoFH preclinical model

Safety Considerations

Taiwan TFDA prescribing information (warnings, contraindications, drug interactions) is not available, as bempedoic acid has not been submitted for Taiwan approval.

Please refer to the FDA Nexletol® package insert for full safety information.

One safety point warrants explicit attention based on data within this Evidence Pack: bempedoic acid carries embryotoxicity risk in animal studies and is contraindicated during pregnancy. One of TxGNN’s predicted indications (rank 10, pregnancy-associated osteoporosis) is therefore immediately disqualified on both mechanistic and safety grounds.

Conclusion and Next Steps

Decision: Proceed with Guardrails (for HoFH indication)

Rationale: A 2026 real-world study directly supports bempedoic acid use in HoFH, and the mechanistic rationale is sound — ACL inhibition provides LDLR-independent LDL-C reduction that can offer partial benefit even when both LDLR alleles are non-functional. Evidence meets L3 threshold with strong biological plausibility.

Note on remaining TxGNN predictions — all Hold:

Rank	Predicted Indication	Reason for Hold
1	Hyperthyroidism	No ACL–thyroid axis mechanistic link; KG topology artifact
2	THRβ resistance	Nuclear receptor pathway; no intersection with ACL/cholesterol synthesis
3	Infectious bovine rhinotracheitis	Veterinary disease; irrelevant to human repurposing
4	Malignant catarrh	Veterinary disease; same KG contamination issue as rank 3
5	CMV infection	No established antiviral mechanism for ACL inhibitors
7	Hyperthyroxinemia	Same thyroid-metabolic KG clustering as rank 1
8	Drug-induced osteoporosis	Bempedoic acid is not the causative drug; no treatment rationale
9	Multiple endocrine neoplasia	KG endocrine node clustering; no mechanistic link
10	Pregnancy-associated osteoporosis	Safety contraindication (embryotoxicity) + no mechanistic basis

To proceed with HoFH evaluation, the following is needed:

Complete safety dossier: Obtain full FDA Nexletol® prescribing information or initiate Taiwan TFDA consultation to understand local submission requirements
MOA documentation: Retrieve full DrugBank DB11936 record to formally document the ACL inhibition mechanism in the dossier
Full-text review: Obtain and critically appraise PMID 41274797 (2026 real-world HoFH study) for specific LDL-C % reduction, sample size, duration, and adverse event profile
HoFH patient landscape in Taiwan: Assess estimated patient population size and whether registry data exist to support a compassionate use or named-patient program prior to full NDA filing
Clinical trial gap: Consider feasibility of a Taiwan Phase 2 open-label study in HoFH, given the complete absence of registered trials globally for this combination
NDA pathway: Bempedoic acid has no Taiwan approval in any indication — a full NDA filing would be required; early scientific advice meeting with TFDA is recommended
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.